Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
TOKYO and GUANGZHOU, China, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Riken Genesis Co., Ltd. ( Riken Genesis ) and Burning Rock Biotech Limited ( NASDAQ: BNR, "Burning Rock" ) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion ...
How this was made

The 30-second read
Why it matters
This approval is likely to enhance BNR's revenue streams and strengthen its position in the personalized medicine market, possibly attracting strategic partnerships.
Market read
The news is highly relevant for investors and traders focusing on biotech and diagnostics sectors, especially those with exposure to Asian markets.
What to watch
Potential delays in product launch, competitive responses from other diagnostics firms, or unforeseen regulatory hurdles could temper the positive outlook.
Background
Burning Rock Biotech Limited has developed the OncoGuide™ OncoScreen™ Plus CDx System, a companion diagnostic for breast cancer treatments. The recent approval in Japan marks a significant milestone, expanding its market reach.
Ticker impact
The news pertains directly to Burning Rock Biotech Limited (BNR), which is the subject company involved in the new diagnostic approval.
Moderate upward price movement expected within the short to medium term.
Regulatory approval in a major market like Japan can lead to increased sales, partnerships, and investor confidence, especially given the company's focus on personalized medicine.
Market effects
The approval may boost investor confidence in the biotech and diagnostics sector, potentially leading to increased valuations for similar companies.
Positive impact on the Japanese biotech market and regional competitors offering similar diagnostics.
Limited direct impact globally, but may influence investor sentiment toward biotech regulatory approvals.
Counterpoint
Regulatory approval does not guarantee commercial success; market acceptance, pricing, and reimbursement policies in Japan could limit revenue growth.
Key entities
- CompanyBurning Rock Biotech Limited
A biotechnology company specializing in cancer diagnostics and personalized medicine.
- PartnerRiken Genesis Co., Ltd.
A collaborator involved in the regulatory approval process.




